Marianne Stanford

Marianne Stanford is the Vice President of Research and Development at IMV Inc. Marianne has been with the company since 2010, and in their current role, they are responsible for leading the company's research efforts and overseeing the development of new immunotherapies and vaccines.

Prior to joining IMV, Marianne worked in the pharmaceutical industry for over 20 years, holding various positions in research and development. Marianne has a deep understanding of the drug development process and has played a key role in the development of several successful drugs and vaccines.

Marianne is a highly skilled scientist and manager, and under their leadership, IMV has made significant progress in the development of new immunotherapies and vaccines. The company's most advanced product, DPX-Survivac, is currently in Phase 2 clinical trials for recurrent lymphoma, and is expected to enter Phase 2 clinical studies for ovarian cancer and glioblastoma in the near future.

Immunovaccine's goal is to out-license its DepoVax platform to partners to generate earlier revenues. With their extensive experience in the pharmaceutical industry, Marianne is well-positioned to lead IMV towards this goal.

Marianne Stanford has a PhD in microbiology and immunology from Dalhousie University, an MSc in Medicine (Immunology) from Memorial University of Newfoundland, and a BSc in Biology from Memorial University of Newfoundland.

Marianne Stanford reports to Jeremy Graff, Chief Scientific Officer. Some of their coworkers include Heather Hirsch - VP, Translational Research.